We have a variety of demonstration Evidence Maps available for you to preview. The examples below allow you to use all the features of the Evidence Maps so that you can see how useful these tools would be for your portfolio.
Use of these demonstration Maps is subject to our terms and conditions.
Treatments for HIV
The purpose of this Evidence Map was to see if data indexed from abstracts could be used together with a network tool in two scenarios:
1. To create a network of sufficient accuracy from available data to rule out if a network meta-analysis (NMA) is feasible.
2. To create a network of sufficient accuracy from available data to assist in planning a phase 3 clinical trial.
We based the Map on an existing systematic review and NMA, and compared the network predictions we could make from the abstracts of each included paper with the results of the full NMA based on the data in the full text publications.
The Map includes 206 abstracts from the original SLR
Each abstract was indexed to a number of fields, including the population, treatment regimens that were compared, trial name and outcomes reported at each timepoint
Although accuracy varied by outcome, the Map was able to predict the networks that could be created for the most common outcomes with high accuracy
The Map can therefore show where an NMA is likely to be unfeasible and is a quick way of identifying the best comparators and outcomes for a Phase 2 or 3 RCT
Improving workplace productivity
We searched PubMed database on the 25th of January 2023 for studies on interventions that could be implemented in a typical workplace, regardless of employee health, to improve work productivity.
The search identified a total of 2730 abstracts of which 92 were relevant and indexed to the following fields:
Age group (how old were the workers)
Country (where was the study done)
Occupational group (who were the workers)
Productivity benefit (outcome)
Productivity measure (how the outcome was assessed)
Research method (type of study)
Setting (type of workplace)
Work place intervention (what was changed)
Year (when the research was published)
Cocoa for mental health, mortality and well-being
We developed an Evidence Map in August 2022, to inform the development of a Global Value Dossier focusing on the impact of cocoa on mental health, mortality and well-being. For the purposes of the dossier, we performed both systematic and targeted searches.
The abstracts in the Map have been indexed to the following fields:
- Value messages
- Value position
- Intervention
- Disease
- Subpopulation
- Study methodology
- Study size
- Locations
- Prevalence of burnout
- Publication year
138 abstracts indexed by topic and to relevant section of GVD.
Abstracts are indexed by whether they support or contradict the value messages in the dossier, showing the strength of the evidence for each point.
Key outcomes e.g. burnout rate have been indexed so users can instantly see the scale of the problem.
Interventions include cocoa, dark chocolate and non-dark chocolate, plus flavonoids and polyphenols.
Most of the studies were from the US, followed by Italy, the UK, Australia, France, Japan and Sweden.
The global value dossier can be downloaded from the Resources page.
Costs and resource use in endometriosis
We searched the heoro.com database in June 2022 for studies on costs and resource use associated with endometriosis. Relevant abstracts were indexed to the following fields:
- Condition
- Features
- Outcomes
- Location
- Study type
- Year
73 abstracts from 26 geographical locations were relevant.
The majority of studies were conducted in the US, followed by Italy, the UK, Brazil and Canada.
Features and complications most commonly reported were pain and infertility, with the economic burden of menorrhagia, pelvic adhesions and ectopic pregnancies assessed less frequently.
Healthcare costs and resource use were most frequently assessed, especially in US studies, but the impact on employment, productivity and careers was reported in 20 studies, in particular those from Europe.
Acute respiratory distress syndrome (ARDS)
We developed an Evidence Map as part of a Rapid Review of the evidence on acute respiratory distress syndrome in April 2020.
This Evidence Map provides an overview of the incidence and prevalence, features, diagnosis, treatment, prognosis, quality of life, costs and resource use and unmet needs of patients with ARDS and their families and caregivers.
The Map was compiled in April 2020, with abstracts sourced from 3 medical databases and grey literature.
486 abstracts are indexed to 10 fields: disease, comorbidity, location, intervention, publication date, topic, study size and methodology, subpopulation and PRO instruments.
47 PRO instruments and 50 interventions are indexed to the publications that cited them.
23 specific interventions were assessed, including anakinra, aviptadil, drotecogin alfa, gimsilumab, hydroxychloroquine, imatinib, interferon beta, palifermin, remdesivir, sarilumab, siltuximab and tocilizumab.
The majority of studies were international or conducted in the US, followed by Germany, Greece, China, Italy and Canada.
Economic evaluations in gastric cancer
We searched heoro.com on June 21st 2022 for economic evaluations of gastric cancer.
The abstracts were indexed according to:
- Type of economic evaluation
- The stage of cancer or other conditions being investigated
- Interventions
- Location
- Publication year
124 publications were included in the Map.
37 of the studies were cost-utility analyses reporting the use of quality adjusted life-years, 32 were cost-effectiveness analyses, and 23 were cost-consequence analyses.
35 evaluated surgical interventions, 52 evaluated methods for screening, surveillance, or cancer staging, and 19 evaluated chemotherapy regimens, including apatinib, paclitaxel, ramucirumab and trastuzumab.
The majority of studies were conducted in China, Japan, the USA, and Korea.
Economic evaluations in rheumatoid arthritis
We searched heoro.com in October 2022 for economic model studies of pharmaceutical or biological therapies in rheumatoid arthritis.
The abstracts were indexed according to the following fields:
- Location
- Interventions
- Study methodology (type of economic evaluation)
- Disease stage (or line of treatment)
- Publication year
153 relevant abstracts were identified by the search.
121 cost-utility models, 27 cost-effectiveness models and 1 cost-benefit model plus 11 systematic reviews were included in the Map.
18 specific drug interventions were evaluated, including abatacept, adalimumab, baricitinib, certolizumab, etanercept, golimumab, infliximab, rituximab, sarilumab, tocilizumab, tofacitinib and non-biological therapies.
The majority of studies were set in the UK, followed by the US, the Netherlands, Sweden and Canada.
The purpose of this Evidence Map was to see if data indexed from abstracts could be used together with a network tool in two scenarios:
1. To create a network of sufficient accuracy from available data to rule out if a network meta-analysis (NMA) is feasible.
2. To create a network of sufficient accuracy from available data to assist in planning a phase 3 clinical trial.
We based the Map on an existing systematic review and NMA, and compared the network predictions we could make from the abstracts of each included paper with the results of the full NMA based on the data in the full text publications.
The Map includes 206 abstracts from the original SLR
Each abstract was indexed to a number of fields, including the population, treatment regimens that were compared, trial name and outcomes reported at each timepoint
Although accuracy varied by outcome, the Map was able to predict the networks that could be created for the most common outcomes with high accuracy
The Map can therefore show where an NMA is likely to be unfeasible and is a quick way of identifying the best comparators and outcomes for a Phase 2 or 3 RCT
We searched PubMed database on the 25th of January 2023 for studies on interventions that could be implemented in a typical workplace, regardless of employee health, to improve work productivity.
The search identified a total of 2730 abstracts of which 92 were relevant and indexed to the following fields:
Age group (how old were the workers)
Country (where was the study done)
Occupational group (who were the workers)
Productivity benefit (outcome)
Productivity measure (how the outcome was assessed)
Research method (type of study)
Setting (type of workplace)
Work place intervention (what was changed)
Year (when the research was published)
We developed an Evidence Map in August 2022, to inform the development of a Global Value Dossier focusing on the impact of cocoa on mental health, mortality and well-being. For the purposes of the dossier, we performed both systematic and targeted searches.
The abstracts in the Map have been indexed to the following fields:
- Value messages
- Value position
- Intervention
- Disease
- Subpopulation
- Study methodology
- Study size
- Locations
- Prevalence of burnout
- Publication year
138 abstracts indexed by topic and to relevant section of GVD.
Abstracts are indexed by whether they support or contradict the value messages in the dossier, showing the strength of the evidence for each point.
Key outcomes e.g. burnout rate have been indexed so users can instantly see the scale of the problem.
Interventions include cocoa, dark chocolate and non-dark chocolate, plus flavonoids and polyphenols.
Most of the studies were from the US, followed by Italy, the UK, Australia, France, Japan and Sweden.
The global value dossier can be downloaded from the Resources page.
We searched the heoro.com database in June 2022 for studies on costs and resource use associated with endometriosis. Relevant abstracts were indexed to the following fields:
- Condition
- Features
- Outcomes
- Location
- Study type
- Year
73 abstracts from 26 geographical locations were relevant.
The majority of studies were conducted in the US, followed by Italy, the UK, Brazil and Canada.
Features and complications most commonly reported were pain and infertility, with the economic burden of menorrhagia, pelvic adhesions and ectopic pregnancies assessed less frequently.
Healthcare costs and resource use were most frequently assessed, especially in US studies, but the impact on employment, productivity and careers was reported in 20 studies, in particular those from Europe.
We developed an Evidence Map as part of a Rapid Review of the evidence on acute respiratory distress syndrome in April 2020.
This Evidence Map provides an overview of the incidence and prevalence, features, diagnosis, treatment, prognosis, quality of life, costs and resource use and unmet needs of patients with ARDS and their families and caregivers.
The Map was compiled in April 2020, with abstracts sourced from 3 medical databases and grey literature.
486 abstracts are indexed to 10 fields: disease, comorbidity, location, intervention, publication date, topic, study size and methodology, subpopulation and PRO instruments.
47 PRO instruments and 50 interventions are indexed to the publications that cited them.
23 specific interventions were assessed, including anakinra, aviptadil, drotecogin alfa, gimsilumab, hydroxychloroquine, imatinib, interferon beta, palifermin, remdesivir, sarilumab, siltuximab and tocilizumab.
The majority of studies were international or conducted in the US, followed by Germany, Greece, China, Italy and Canada.
We searched heoro.com on June 21st 2022 for economic evaluations of gastric cancer.
The abstracts were indexed according to:
- Type of economic evaluation
- The stage of cancer or other conditions being investigated
- Interventions
- Location
- Publication year
124 publications were included in the Map.
37 of the studies were cost-utility analyses reporting the use of quality adjusted life-years, 32 were cost-effectiveness analyses, and 23 were cost-consequence analyses.
35 evaluated surgical interventions, 52 evaluated methods for screening, surveillance, or cancer staging, and 19 evaluated chemotherapy regimens, including apatinib, paclitaxel, ramucirumab and trastuzumab.
The majority of studies were conducted in China, Japan, the USA, and Korea.
We searched heoro.com in October 2022 for economic model studies of pharmaceutical or biological therapies in rheumatoid arthritis.
The abstracts were indexed according to the following fields:
- Location
- Interventions
- Study methodology (type of economic evaluation)
- Disease stage (or line of treatment)
- Publication year
153 relevant abstracts were identified by the search.
121 cost-utility models, 27 cost-effectiveness models and 1 cost-benefit model plus 11 systematic reviews were included in the Map.
18 specific drug interventions were evaluated, including abatacept, adalimumab, baricitinib, certolizumab, etanercept, golimumab, infliximab, rituximab, sarilumab, tocilizumab, tofacitinib and non-biological therapies.
The majority of studies were set in the UK, followed by the US, the Netherlands, Sweden and Canada.